Compare Fifth Third Bancorp Common Stock (FITB) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fifth Third Bancorp Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? Fifth Third Bancorp Common Stock trades at $50.28 (market cap $45.54B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Fifth Third Bancorp Common Stock is far larger — about 6.1× Spyre Therapeutics Inc. Common Stock's market cap, and Fifth Third Bancorp Common Stock pays a 3.35% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fifth Third Bancorp Common Stock for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FITB | SYRE | |
|---|---|---|
Market Cap | $45.54B | $7.52B |
Volume | 4,742,681 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $59.37 | $108.92 |
52-Week Low | $40.36 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $63.41B | $6.52B |
Dividend Yield | 3.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fifth Third Bancorp (FITB) trades at $50.22, down 1.18% with bearish technical signals from moving averages. The stock shows solid fundamentals with a 22.36% net income margin and has beaten earnings expectations in two of the last three quarters. Recent news highlights the bank's innovation banking launch and Q3 guidance tracking at the high end of ranges post-Comerica conversion. Analyst consensus remains strongly positive with a $62.63 price target representing 25% upside potential.
FITB presents a compelling value opportunity with reasonable valuation multiples (P/E 16.91, P/B 1.41) and strong profitability metrics. Key risks include regulatory scrutiny of banking practices and integration challenges from the Comerica acquisition. The upcoming Q3 earnings report on October 19 will be crucial for validating the bank's growth trajectory and capital management strategy.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fifth Third Bancorp Common Stock
Fifth Third Bancorp provides retail and commercial banking, lending, payments, and wealth management services in the United States.
Read more on FITB →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
